MedTrace Logo

To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients

NCT01817855 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2016-03-30

Study results available
· View outcomes & findings →

Summary

This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD7624 in healthy subjects and patients with chronic obstructive pulmonary disease.

Conditions

  • COPD
  • Healthy Subjects

Interventions

DRUG

AZD7624

Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer

DRUG

Placebo to match

Multiple doses inhaled placebo via a nebulizer

Sponsors & Collaborators

Principal Investigators

  • Saeed Khan, MBBS, MRCP · Quintiles Drg Research Centre At Guys Hosipital, 6 Newcomen Street London SE1 1YR

  • Naimish Patel, MD · AstraZeneca, Wilmington, US

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01817855 on ClinicalTrials.gov